Management of Bronchitis
For acute bronchitis, do not prescribe antibiotics, antitussives, bronchodilators, or corticosteroids—provide supportive care and patient education about the expected 2-3 week duration of cough. 1
Acute Bronchitis Management
Initial Assessment
The most recent CHEST guidelines (2020) provide clear direction: acute bronchitis is a clinical diagnosis requiring no routine investigations 1. Specifically avoid:
- Chest x-ray
- Spirometry or peak flow
- Sputum cultures
- Viral PCR testing
- C-reactive protein or procalcitonin
Critical caveat: This applies only to immunocompetent adult outpatients. If symptoms persist or worsen, reassessment with targeted investigations (chest x-ray, sputum culture, peak flow, CBC, CRP) becomes appropriate 1.
Treatment Approach
The evidence is unequivocal: no pharmacologic therapy is recommended 1. This includes:
- No antibiotics (reduce cough by only 0.5 days while exposing patients to adverse effects) 2
- No antitussives
- No inhaled beta-agonists or anticholinergics
- No inhaled or oral corticosteroids
- No oral NSAIDs
Patient Education Strategy
The cornerstone of management is setting realistic expectations: cough typically lasts 2-3 weeks 2, 3. Effective strategies to reduce inappropriate antibiotic prescribing include:
- Describing the condition as a "chest cold" rather than "bronchitis"
- Delayed antibiotic prescriptions (if patient insists)
- Explicit discussion of antibiotic risks (allergic reactions, C. difficile, nausea)
When to Reconsider
Antibiotics may be considered only if 1:
- Symptoms worsen suggesting bacterial superinfection
- Patient has underlying chronic lung disease (asthma, COPD, bronchiectasis)
- Pertussis is suspected (cough >2 weeks with paroxysms, whooping, post-tussive emesis)
Important pitfall: Up to 65% of patients with recurrent "acute bronchitis" episodes actually have undiagnosed mild asthma 1. Consider this diagnosis in patients with multiple similar episodes.
Chronic Bronchitis Management
Stable Disease
For stable chronic bronchitis, the treatment hierarchy is: (1) smoking cessation, (2) ipratropium bromide, (3) short-acting beta-agonists, with theophylline as third-line 4.
First-Line: Smoking Cessation
90% of patients achieve cough resolution with smoking cessation—this is the single most effective intervention 4. This applies equally to passive smoke exposure and workplace irritant avoidance.
Bronchodilator Therapy
Ipratropium bromide is the preferred bronchodilator for chronic cough in stable chronic bronchitis (Grade A recommendation) 4. It demonstrably:
- Reduces cough frequency
- Decreases cough severity
- Reduces sputum volume
Short-acting beta-agonists (Grade A) should be used primarily for bronchospasm and dyspnea; evidence for cough reduction is inconsistent 4.
Theophylline (Grade A) improves cough but requires careful monitoring due to narrow therapeutic window and drug interactions, particularly in elderly patients 4.
Corticosteroids
Inhaled corticosteroids combined with long-acting beta-agonists are recommended when 4:
- FEV1 <50% (severe/very severe obstruction)
- History of frequent exacerbations
Oral corticosteroids have no role in stable disease due to lack of benefit and significant side effects 4.
What NOT to Use
- No prophylactic antibiotics (Grade I recommendation) 4
- No expectorants (unproven benefit) 4
- No postural drainage or chest percussion (Grade I) 4
Acute Exacerbations of Chronic Bronchitis
For acute exacerbations, use bronchodilators first, add antibiotics for severe exacerbations (especially with purulent sputum), and give a 10-15 day course of systemic corticosteroids 4.
Bronchodilator Management
Start with either short-acting beta-agonist OR anticholinergic (Grade A) 4. If inadequate response at maximal dose, add the other agent.
Do NOT use theophylline during acute exacerbations (Grade D recommendation) 4—evidence shows no benefit and significant risk.
Antibiotic Therapy
Antibiotics are recommended (Grade A) for acute exacerbations, particularly when 4:
- All three cardinal symptoms present (increased cough, sputum volume, dyspnea)
- Purulent sputum
- Severe baseline airflow obstruction
- Severe exacerbation
The 2006 ACCP guidelines acknowledge FDA concerns about trial methodology but still recommend antibiotics based on meta-analysis showing benefit in severe cases 4.
Corticosteroid Therapy
Give systemic corticosteroids for 10-15 days (Grade A) 4:
- Oral route for outpatients
- IV route for hospitalized patients
- Evidence shows equivalence between 2-week and 8-week courses; use shorter duration to minimize side effects
What NOT to Use During Exacerbations
- No expectorants (Grade I) 4
- No postural drainage/chest percussion (Grade I) 4
- No theophylline (Grade D) 4
Symptomatic Cough Relief
Central cough suppressants (codeine, dextromethorphan) are recommended for short-term symptomatic relief in both stable and exacerbated chronic bronchitis 4.